Furthermore, as the HIF pathway drives pleiotropic downstream events in cancers, it will be intriguing to examine whether tumors that acquire resistance to the recently developed HIF-2α inhibitors55,56 retain their ferroptosis susceptibility and sensitivity to GPX4 inhibition, and if so, whether GPX4 inhibitors will be useful to treat these otherwise drug-resistant cancers. The gene discussed is GPX4; the disease is cancer.